PDF(Pubmed)
Abstract：
Bevacizumab, an anti-vascular epidermal growth factor inhibitor, is approved for the treatment of various cancers. Hypertension, gastrointestinal perforation, bleeding manifestations, impaired wound healing, and cerebrovascular accidents are common side effects associated with the monoclonal antibody. Uncommon cutaneous reactions like exfoliative dermatitis associated with bevacizumab have been documented in the medical literature. We present an unusual case of bevacizumab-induced cutaneous lupus in a patient with metastatic colon cancer that started resolving after discontinuing chemotherapy. Timely intervention was key in preventing the progression of this chemotherapy-induced cutaneous lupus.
摘要：
贝伐单抗,一种抗血管表皮生长因子抑制剂，被批准用于治疗各种癌症。高血压,胃肠穿孔,出血表现，伤口愈合受损，脑血管意外是与单克隆抗体相关的常见副作用。医学文献中已经记录了罕见的皮肤反应，例如与贝伐单抗相关的剥脱性皮炎。我们介绍了一例转移性结肠癌患者贝伐单抗诱导的皮肤狼疮的罕见病例，该病例在停止化疗后开始消退。及时干预是预防这种化疗诱导的皮肤狼疮进展的关键。
